Low-risk prostate cancer well managed with active surveillance

The level II code A9616 will be effective starting on October 1, 2025.

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.